TABLE 1.
Results of the network meta-analysis of the HbA1c (upper right quarter) and the body weight (lower left quarter).
| Tirzepatide 5 mg | −0.80 (−1.57, −0.03) | −0.40 (−1.17,0.37) | −0.13 (−1.03,0.78) | 0.70 (0.24,1.15) | 0.50 (−0.26,1.26) |
|---|---|---|---|---|---|
| 6.50 (3.03,9.97) | Tirzepatide 15 mg | 0.40 (−0.38,1.18) | 1.70 (0.93,2.47) | 1.50 (0.60,2.40) | 1.30 (0.53,2.07) |
| 3.90 (0.51,7.29) | −2.60 (−6.09,0.89) | Tirzepatide 10 mg | 0.11 (−0.78,0.99) | 1.10 (0.20,1.99) | 0.90 (0.13,1.67) |
| −2.26 (−6.28,1.76) | −4.40 (−7.80, −1.00) | −1.45 (−5.36,2.46) | Placebo | −1.00 (−1.90, −0.11) | −1.20 (−1.97, −0.43) |
| −9.37 (−11.33, −7.41) | −15.87 (−19.85, −11.89) | −13.27 (−17.19, −9.36) | −4.97 (−8.89, −1.05) | Insulin | −0.20 (−1.08,0.69) |
| −2.10 (−5.47,1.27) | −8.60 (−12.08, −5.12) | −6.00 (−9.40, −2.60) | 2.30 (−1.11,5.71) | 7.27 (3.37,11.17) | GLP1-RA |
The differences between the compared groups were deemed as significant when the 95% CI, did not contain 0.00, which is marked with grey background.